Compare ATOS & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATOS | ATCH |
|---|---|---|
| Founded | 2009 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 34.9M |
| IPO Year | 2010 | 2024 |
| Metric | ATOS | ATCH |
|---|---|---|
| Price | $4.88 | $0.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $28.33 | $1.00 |
| AVG Volume (30 Days) | 73.1K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $1,758.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.14 |
| 52 Week High | $7.56 | $1.92 |
| Indicator | ATOS | ATCH |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 64.18 |
| Support Level | $4.59 | $0.17 |
| Resistance Level | $5.12 | $0.24 |
| Average True Range (ATR) | 0.47 | 0.01 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 14.67 | 92.99 |
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.